• Home
  • About
  • All Companies
    • Recent
    • Summary Lists
  • Contact

Lento Bio

  • June 7, 2022
  • New Biotech Startups

Lento Bio was founded in 2022 in collaboration with Ichor Life Sciences and Clarkson University’s Shipley Center for Innovation, with the goal to develop effective, safe, and durable treatments for chronic age-related disease by using small molecules to directly target molecular damage.

The company’s primary focus is the removal of Advanced Glycation End Products (AGEs), initially focusing on damage to the lens in presbyopia while also exploring further opportunities in systemic disease.

According to the company, age-related diseases stem from multiple forms of damage across cells and tissues; what starts as the accumulation of individual harmful molecules can end up driving high-level disease phenotypes. One form of molecular damage, glycation, gives rise to irreversible modifications termed Advanced Glycation End Products (AGEs) which can damage tissues during aging and diabetes. Potential therapeutic compounds developed by LentoBio will cleave or inhibit the formation of AGEs.

In presbyopia, a condition occurring near ubiquitously starting in middle-age, the link with glycation is direct; the lens of the eye becomes stiff due to cross-linking between its crystallin proteins, resulting in stiffness and thus near-vision loss. Lento Bio plans to develop eyedrops employing small molecule therapeutics to reduce AGE crosslinks in the lens, potentially providing durable relief from presbyopia symptoms without the need for corrective lenses.


Subscribe for alerts on new companies featured on Startups.Bio


January 25, 2023MxT Biotech
MxT Biotech, a Korea University spin-out, aims to transform cancer immunotherapy, cellular engineering and genome editing with its patented non-viral genome editing technology. The Hydroporator™ is a non-viral microfluidic platform …
November 25, 2022Vilya
Vilya is a spin-out of the University of Washington Institute for Protein Design (IPD), with a platform to design membrane-permeable peptides with high structural accuracy, opening up a new class …
November 16, 2022VentureRadar’s Top 100 Emerging Biotech Start-ups Report
Biotechnology is in the midst of a exciting era of innovation, with an ever-expanding toolbox of modalities and approaches spawning development of exciting new vaccines, medicines and therapies. VentureRadar's Top …
November 2, 2022CorriXR Therapeutics
CorriXR Therapeutics is an oncology-focused biotherapeutics developing a novel gene editing platform technology. CorriXR has developed an innovative CRISPR/Cas molecule that disables the genome of a tumor cell but not …

View all recently featured startups


Tags:

© Copyright 2022. Startups.Bio, powered by VentureRadar.